Demystifying HTA: patients’ role in new legislation
“Earlier this year, the EU Regulation on Health Technology Assessment (HTA) – a deliverable of the EU Pharmaceutical Strategy – entered into force, marking an important step towards improving access to innovative technologies. However, this does not mean the legislation applies immediately – a three-year transitional period has been set up during which a new governance framework will be established to ensure effective application across the EU as of 2025. 
The new Regulation, which has been a key EURORDIS advocacy priority, does not come out of nowhere. It is built upon a system of voluntary cooperation between the Member States, which has taken shape through EU-funded initiatives – HTA Network and the EU-funded EUnetHTA Joint Actions. The legislation, therefore, formalises existing partnerships by introducing a permanent framework for joint work that will also cover joint scientific consultations, the identification of emerging health technologies, and voluntary cooperation, as well as work on joint clinical assessments.
Ahead of the first meeting on 21 April of the new EU HTA Coordination Group – a governing body whose composition is yet unknown – we are taking the opportunity to go back to basics and remind ourselves what HTA is, what the role of the patient community has been and why patients’ input is so critical for the new Regulation to succeed“.
More info: https://www.eurordis.org/demystifying-hta/
OpenEdition vous propose de citer ce billet de la manière suivante :
egennet (20 juillet 2022). Demystifying HTA: patients’ role in new legislation. ELSIBI. Consulté le 19 février 2026 à l’adresse https://doi.org/10.58079/o60r





